Biopharma | Karius

Hero Biopharma

Karius Laboratory Service for Pathogen Biomarker Detection

Precision medicine lab service to drive efficiency in biopharmaceutical clinical development

Karius offers pathogen biomarker detection as a lab service to biopharmaceutical companies. Our technology is based on next-generation sequencing of microbial cell-free DNA in plasma.

Partnering with Karius can help accelerate your clinical trials in a number of ways, including identification of difficult-to-detect pathogens with a rapid turnaround time, quantitative monitoring of pathogen DNA on therapy, and direct detection in plasma of potential co-infections.


  • Current tests detect only one or a small panel of pathogens.
  • Testing for a range of pathogens with multiple assays is expensive and time-consuming.
  • Patients may be enrolled into studies based on presumed clinical infection rather than on direct microbiologic confirmation.

Karius Laboratory Service

A plasma-based next-generation sequencing test that can rapidly identify more than a thousand pathogens from a single blood draw.


Precise, broad-based detection of bacteria, DNA viruses, fungi/molds, and protozoa.

CLIA-certified, CAP-accredited clinical laboratory with dedicated program and data management support.

Clinical Trial Applications

Rapid detection and monitoring of pathogens may be useful in these and other clinical trial scenarios:

  • Potential selection of eligible subjects
  • Monitoring drug efficacy
  • Coding and adjudication of adverse events
  • Assisting with determination of dosing and duration of treatment
  • Identification of co-infections that could impact therapeutic efficacy, safety and adverse event reporting

For more information or to discuss pathogen biomarker detection in your clinical trials, please contact us at


For additional publications, abstracts, and clinical trials, visit